UMMS Affiliation

Division of Dermatology, Department of Medicine; UMass Metoblic Network

Publication Date


Document Type



Dermatology | Skin and Connective Tissue Diseases


In this issue of JAMA Dermatology, Speeckaert and colleagues report that levels of the soluble CD25 and CD27 molecules (sCD25 and sCD27) are elevated in the serum of patients with active vitiligo compared with patients with stable disease. In addition, sCD25 levels were found to be significantly lower in the serum of patients being treated with topical immunosuppressants (including steroids and calcineurin inhibitors) and the serum level of sCD27 was significantly lower in patients with recent repigmentation, suggesting a potential to use these as biomarkers to monitor treatment responses. Interestingly, the authors continued to prospectively study a relatively large number of participants and demonstrated that serum levels of both sCD25 and sCD27 were associated with disease progression during follow-up. These important findings suggest that monitoring of these markers in the serum of patients with vitiligo may provide a glimpse into what is happening in the skin, a process that is not obvious by simple observation in vitiligo, in contrast to more inflammatory diseases.

Rights and Permissions

Publisher PDF posted after 12 months as allowed by the publisher's author rights policy at

DOI of Published Version



JAMA Dermatol. 2016 Nov 1;152(11):1187-1188. doi: 10.1001/jamadermatol.2016.2501. Link to article on publisher's site

Journal/Book/Conference Title

JAMA dermatology

Related Resources

Link to Article in PubMed

PubMed ID